Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

51.53 +0.02 (+0.04%)
Official Closing Price Updated: 7:00 PM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
45 46 Next >
News headline image
Down 75%. Is Agenus Stock a Buy on the Dip? ↗
Wall Street analysts who watch the cancer drug developer closely think it could rocket higher. 
Via The Motley Fool
News headline image
CureVac, GS Partner Release Data On Influenza Vaccine Study ↗
CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A... 
Via Benzinga
News headline image
In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster ↗
Sanofi reaches a settlement in principle for about 4,000 Zantac lawsuits in the US, excluding Delaware, regarding alleged cancer risks linked to NDMA. Financial terms remain undisclosed. 
Via Benzinga
Topics Lawsuit
News headline image
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia 
Via MarketBeat
News headline image
Peering Into GSK's Recent Short Interest ↗
 
Via Benzinga
News headline image
2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now? ↗
These stocks could rocket higher, but they also present significant risks. 
Via The Motley Fool
News headline image
Russell 2000 Index Best And Worst Performing Stocks Of 2024 ↗
The Russell 2000 index continued to underperform the Dow Jones and Nasdaq 100 indices in the first quarter of 2024. 
Via Talk Markets
Topics Stocks
News headline image
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback ↗
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
News headline image
Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead? ↗
Several well-regarded funds run by famous billionaire investors bought shares of 23andMe during the last three months of 2023. 
Via The Motley Fool
News headline image
Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month ↗
GSK caps asthma and COPD medicine costs at $35/month, effective Jan 1, 2025. Includes Advair, Breo, Ventolin. Follows AstraZeneca's suit for their respiratory medicines. Sanders applauds move amid... 
Via Benzinga
News headline image
GSK Reveals New Phase 3 Data For Jemperli Combo Therapy To Support Expanded Use Approval For Wider Endometrial Cancer ↗
Latest advancements in endometrial cancer treatment with GSK's Jemperli (dostarlimab)! Explore promising overall survival and progression-free survival results from the RUBY trial, paving the way for... 
Via Benzinga
News headline image
Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B ↗
Pfizer to reduce stake in Haleon to approximately 24% following earlier divestment announcement. Offer price per share to be revealed post book-building process by Haleon. 
Via Benzinga
News headline image
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
From GSK plc
Via Business Wire
News headline image
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio ↗
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses. 
Via InvestorPlace
News headline image
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead ↗
Don't fall for the siren song of penny stocks. Rather, fill your portfolio with companies that have a proven track record of success. 
Via InvestorPlace
News headline image
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach' ↗
Goldman Sachs urges investors to diversify geographically due to high concentration in US tech stocks, with Japan, healthcare, and European GRANOLAS highlighted as promising markets. 
Via Benzinga
News headline image
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise ↗
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth. 
Via InvestorPlace
News headline image
GSK's Withdrawn Multiple Myeloma Drug Shows Encouraging Combination Therapy Data In Second Late-Stage Study ↗
GSK's DREAMM-8 trial reveals positive interim results for Blenrep combo in relapsed multiple myeloma. Improved progression-free survival and overall survival trend observed. 
Via Benzinga
News headline image
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
From GSK plc
Via Business Wire
News headline image
Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data Shows ↗
Findings from ViiV Healthcare's LATITUDE trial on long-acting HIV treatment. Cabenuva demonstrates superior efficacy in viral load suppression compared to daily oral therapy. Key secondary endpoints... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Pfizer/GSK-Backed ViiV Healthcare's HIV Drug Associated With Increased Resistance, WHO Report Says ↗
WHO's latest HIV Drug Resistance Report reveals trends in drug resistance. Discover insights on dolutegravir's impact, challenges in HIVDR monitoring, and recommendations for standardized... 
Via Benzinga
News headline image
Crucial Battle Over Healthcare Mandates: Biden Administration Defends Preventive Care Coverage Amidst Legal Challenges ↗
The Biden administration wants insurers to cover preventive care, facing opposition from businesses led by Braidwood Management. 
Via Benzinga
News headline image
Advil Maker Haleon Expects Higher 2024 Revenue After Strong 2023 Earnings, Stock Soars ↗
Haleon reports FY 2023 revenue growth of 4.1% to £11.3 billion ($14.03 billion), missing consensus. Adjusted operating profit rises 10.4% to £2.55 billion. CEO Brian McNamara outlines solid financial... 
Via Benzinga
News headline image
GSK Settles Another California Lawsuit On Heartburn Drug Zantac Causing Cancer, Second Within A Month ↗
GSK settles California lawsuits over Zantac cancer allegations. Confidential agreements reached, cases dismissed. 
Via Benzinga
Topics Lawsuit
News headline image
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields ↗
A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year. 
Via Benzinga
News headline image
GSK's Gepotidacin Oral Antibiotic Non-Inferior To Commonly Used Muscle-Injected Antibiotic Combo For Sexually Transmitted Infection ↗
Results from GSK's EAGLE-1 phase 3 trial on gepotidacin, an oral antibiotic for uncomplicated urogenital gonorrhea. Non-inferior to leading treatment, it offers a potential solution amid rising... 
Via Benzinga
News headline image
3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List ↗
Undervalued small-cap stocks are great for investors seeking options for upside potential, typically at a cheap share price. 
Via InvestorPlace
News headline image
Why Range-Bound Moderna Could Get A Boost On Its Fourth-Quarter Report ↗
The company unexpectedly came in with fourth-quarter earnings that beat projections. 
Via Investor's Business Daily
News headline image
Moderna Stock Q4 Earnings Preview: RSV mRNA Vaccine Scrutiny, Diminishing Spikevax Revenue, FDA Approval In Focus ↗
Moderna reports Q4 earnings on Feb. 22. Analysts expect $2.53B in revenue. Stock has faced challenges but potential for recovery with COVID-19 vaccine and FDA approval in 2024. 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.